EQS-Adhoc

Tilmann Bur succeeds Gregor Siebert as CEO of PAION AG

EQS-Ad-hoc: PAION AG / Key word(s): Personnel Tilmann Bur succeeds Gregor Siebert as CEO of PAION AG 14-Aug-2023 / 15:14 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Tilmann Bur succeeds Gregor Siebert as CEO of PAION AG

 

• Tilmann Bur appointed to the Management Board as CEO effective 01 September 2023
• As planned, Gregor Siebert as interim CEO will leave the Management Board on 30 September 2023 and will then continue to use his experience gained strategically as a member of the Supervisory Board of PAION

 

Aachen, 14. August 2023 - The specialty pharmaceutical company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that Tilmann Bur has been appointed to the Management Board effective 01 September 2023 and will succeed Gregor Siebert as CEO of PAION AG.

Mr. Gregor Siebert had been appointed by the Supervisory Board of PAION AG as a member of the Management Board and CEO on an interim basis pursuant to Sec. 105 (2) AktG for a period from 01 December 2022 to 30 November 2023. Mr. Siebert, in cooperation with Mr. Bur, will ensure an orderly transfer of his field of responsibilities and will step down from the Management Board as of 30 September 2023. It is planned that he will then take Dr. Sickinger's place on the Supervisory Board in the near future, who will resign his mandate for this purpose on 30 September 2023.

End of inside information

###

End of Inside Information

---

Information and Explanation of the Issuer to this announcement:

Tilmann Bur has 20 years of international management experience with a focus on sales and marketing.

Mr. Bur has extensive experience in professional relationship management with decision makers in clinics as well as in setting up and managing national and international sales organizations and dealer networks. He knows the purchasing structures in the European hospital market and is well-versed in KOL management and clinical marketing. Among other positions, Mr. Bur was a member of the executive board at R-Biopharm, at Biosafe and managing director at Haemonetics. Since June 2019, Mr. Bur has been a member of the Management Board and most recently CEO of CO.DON AG, during that time he has played a key role in securing CO.DON's continued business operations.